Amgen today announced AmgenTM
Oncology Assistance (AOA), a comprehensive, multi-faceted financial assistance program that will include a "cap" on out-of-pocket co-payments for cancer patients receiving VectibixTM
(panitumumab). Through AOA, patients who are uninsured, underinsured, or unable to afford their insurance co-payments will receive help obtaining financial support for Amgen's cancer medicines.
"We recognize that treating cancer is expensive and our industry needs to find new ways to ease the financial burden on cancer patients, their families and society," said Kevin Sharer, chairman and chief executive officer at Amgen. "Our goal is to create the most comprehensive oncology access program in the industry, and we are starting with Amgen Oncology Assistance. To ensure patients have access to Vectibix, we have priced it at approximately 20 percent less than the other antibody on the market and created the Vectibix Cap, which is the first of its kind for colorectal cancer patients."
The AOA program will be available for U.S. cancer patients and will launch in October. AOA will expand and consolidate the company's existing financial assistance programs into a simplified package with a single gateway:
- The new Vectibix Cap will limit total patient co-payments for Vectibix in the United States, regardless of income or insurance status. Once a patient reaches the cap (five percent of their adjusted gross income), he or she will become eligible for the SAFETY NET® Foundation.
- The SAFETY NET Foundation is a well-established patient assistance program that provides Amgen oncology medicines at no cost to qualifying uninsured patients. Available to patients with household adjusted gross incomes of up to $75,000 per year, The SAFETY NET Foundation is one of the most generous oncology product donation programs in the industry.
- Amgen also donates millions of dollars to independent third-p
arty administered patient assistance programs to help reduce the financial burden for uninsured or low-income patients.
These programs build on Amgen's Reimbursement Connection®, which has been addressing the provider community's reimbursement questions regarding Amgen therapies for more than 15 years. For more information about Amgen Oncology Assistance, please visit www.amgen.com.
Related biology news :1
. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research2
. Agilent Technologies introduces high-capacity human protein removal system for proteomics research3
. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 20204
. Lipids get new comprehensive classification system5
. NIH launches comprehensive effort to explore cancer genomics6
. RNA map provides first comprehensive understanding of alternative splicing7
. LIAI completes worlds most comprehensive analysis on influenza virus data8
. Costly breeding programs for endangered species pay off9
. Investment level in HIV prevention programs related to HIV incidence in the United States10
. Viral DNA sequence a possible trigger for breast cancer11
. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer